Clinical trial
Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With…
NCT00006390 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00006390 |
|---|---|
| Title | Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia |
| Official title | Phase II Study of Campath-1H (NSC #950010) and Peripheral Blood Stem Cell Transplant for Patients With Chronic Lymphocytic Leukemia |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug, Procedure, Radiation |
| Interventions | alemtuzumab, filgrastim, cyclophosphamide, peripheral blood stem cell transplantation, radiation therapy |
| Start date | Jul 5, 2001 |
| Primary completion | Dec 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 22, 2023 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: